HC Wainwright set a $5.00 price objective on Pieris Pharmaceuticals (NASDAQ:PIRS) in a report published on Wednesday morning, The Fly reports. The firm currently has a buy rating on the biotechnology company’s stock.
Separately, BidaskClub upgraded shares of Pieris Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Pieris Pharmaceuticals has an average rating of Buy and a consensus price target of $10.00.
Shares of Pieris Pharmaceuticals stock traded down $0.30 on Wednesday, hitting $3.56. 610,604 shares of the company’s stock were exchanged, compared to its average volume of 455,000. The stock has a market capitalization of $204.79 million, a PE ratio of -8.90 and a beta of 1.94. Pieris Pharmaceuticals has a 1 year low of $3.24 and a 1 year high of $9.75.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 19.35%. The company had revenue of $8.35 million for the quarter, compared to analysts’ expectations of $6.16 million. On average, equities research analysts expect that Pieris Pharmaceuticals will post -0.49 EPS for the current fiscal year.
In other news, Director Christopher P. Kiritsy bought 5,000 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were bought at an average price of $5.11 per share, for a total transaction of $25,550.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $51,100. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.07% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in PIRS. A.R.T. Advisors LLC bought a new stake in Pieris Pharmaceuticals in the 1st quarter valued at $103,000. Public Employees Retirement System of Ohio bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $110,000. Marshall Wace LLP bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $118,000. Fox Run Management L.L.C. bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $124,000. Finally, Bowling Portfolio Management LLC bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $156,000. Institutional investors own 65.26% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Read More: Should You Consider an Index Fund?
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.